IPP Bureau
Shilpa Medicare receives approval for 2-Deoxy-2-Glucose powder
By IPP Bureau - September 01, 2021
The powder is approved for the treatment of adjunct therapy in moderate to severe Covid-19 patients
.jpg "Pharma tops India’s exports from SEZs")
Pharma tops India’s exports from SEZs
By IPP Bureau - September 01, 2021
As of June 30, 2021, 267 out of a total of 427 SEZs approved by the government are operational
.jpeg "Ami Organics bets on strategic acquisitions as its IPO opens on Sept 1")
Ami Organics bets on strategic acquisitions as its IPO opens on Sept 1
By IPP Bureau - September 01, 2021
The company aims to continue its expansion via organic and inorganic routes to increase production capacity and product portfolio
WHO releases compendium of innovative health technologies
By IPP Bureau - September 01, 2021
The Covid-19 pandemic has exposed the divide that exists between rich and developing nations and to address these challenges the World Health Organisation (WHO), has compiled a list of innovative health technologies that aim to bridge the gap
Zymo Research receives CE Mark for new Covid-19 SafeCollect kits
By IPP Bureau - September 01, 2021
Self-collection devices designed for ease of use and safety
Positive results from Pfizer’s Phase 3 trail comparing efficacy of abrocitinib and dupilumab
By IPP Bureau - September 01, 2021
JADE DARE trial met co-primary and key secondary endpoints and demonstrated a safety profile consistent with previous studies for moderate to severe atopic dermatitis
SK Bioscience and GSK start Phase 3 trial of an adjuvanted COVID-19 vaccine candidate
By IPP Bureau - September 01, 2021
Advance to Phase 3 follows positive interim Phase 1/2 immunogenicity and safety data. The global clinical trial will evaluate vaccine candidate GBP510 against the AZ/Oxford COVID-19 vaccine
Metropolis Healthcare opens new testing centre in Thalassery, Kerala
By IPP Bureau - September 01, 2021
The lab will offer about 4,000 different tests ranging from basic to high-end molecular diagnostic tests
Two major hospitals in Gujarat announce tie-up
By IPP Bureau - September 01, 2021
Aashka Hospitals has entered into a non-binding agreement for its proposed tie-up with Vaidehi—Backbone hospital, Rajkot
Sher-I-Kashmir Institute of Medical Sciences and Medtronic partner to open Surgical Skills Lab
By IPP Bureau - September 01, 2021
The lab has been developed to aid surgeons to overcome the challenging learning curve to obtain laparoscopic expertise
US FDA clears InnoCare’s clinical trial of pan-TRK Inhibitor ICP-723
By IPP Bureau - August 31, 2021
The clinical trial will evaluate the safety, tolerability and pharmacokinetic properties of ICP-723 in patients with solid tumours, and evaluate the anti-tumour efficacy of ICP-723 on NTRK fusion-positive cancers
US FDA grants Lantern Pharma additional Orphan Drug tag for LP-184
By IPP Bureau - August 31, 2021
The drug is also intended for the treatment of glioblastoma multiforme
Sun Pharma to commercialise Winlevi in the US and Canada
By IPP Bureau - August 31, 2021
Acne affects up to 50 million Americans annually. The last FDA approval of an acne drug with a new MOA occurred nearly 40 years ago
Sanofi’s Dupixent pivotal trial meets all primary and secondary endpoints for treatment of atopic dermatitis
By IPP Bureau - August 31, 2021
Results reinforce the well-established safety profile of Dupixent - the first-ever biologic medicine for atopic dermatitis currently approved for patients as young 6 years old
Dr. Reddy's announce launch two drugs in the US market
By IPP Bureau - August 31, 2021
Chlordiazepoxide Hydrochloride and Clidinium Bromide Capsules, USP are available in one strength of 5 mg/2.5 mg capsules in bottle count sizes of 100
